Sir,

I read an article entitled "Heparin-induced thrombocytopenia (HIT) -- Type 2"\[[@ref1]\] with interest. I would like to congratulate author for his effort to concise such a topic in a nice manner. However, I would like to add few more information regarding this entity which you may find useful \[[Table 1](#T1){ref-type="table"}\].

###### 

Features of HIT
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Pretest probability is calculated on the basis of 4Ts: Thrombocytopenia, timing of thrombocytopenia, thrombosis, other cause of thrombocytopenia. Probability is high if more than 50% drop in platelet count after 5 days of initiation of heparin and new development of thrombosis with no other cause for thrombocytopenia.

I would like to summarize the treatment for HIT: Stop heparin, postpone warfarin until substantial recovery in platelet count, avoid platelet transfusions,\[[@ref3]\] start alternative anticoagulants like lepirudin and argatroban (direct thrombin inhibitor), danaparoid, or fondaparinux (factor Xa inhibitor).

Fondaparinux is a synthetic heparin pentasaccharide which does not cross-react with HIT antibodies and can be used for the treatment of HIT.\[[@ref4]\]
